ABSTRACT
Amyloid-beta peptide (Abeta) is believed to be a central player in the Alzheimer disease (AD) pathogenesis. However, its mechanisms of toxicity to the central nervous system are unknown. To explore this area, investigators have recently focused on Abeta-induced cellular dysfunction. Extensive research has been conducted to investigate Abeta monomers and oligomers, and these multiple facets have provided a wealth of data from specific models. Abeta appears to be accumulated in neuronal mitochondria and mediates mitochondrial toxicity. Mitochondrial dysfunction became a hallmark of Abeta-induced neuronal toxicity. Mitochondria are currently considered as primary targets in the pathobiology of neurodegeneration. This review provides an overview of the Abeta toxicity to isolated mitochondria, mitochondria in different tissues and cells in vitro and in vivo. Full texts and abstracts from all 530 biomedical articles listed in PubMed and published before January 2014 were analysed. The mechanisms underlying the interaction between Abeta and mitochondrial membranes and resulting mitochondrial dysfunction are most disputed issues. Understanding and discussing this interaction is essential to evaluating Abeta effects on various intracellular metabolic processes. 
INTRODUCTION
Alzheimer's disease (AD) is a classic example of a condition in which learning, memory and cognitive function decline simultaneously, dramatically and permanently. This chronic illness progresses quite slowly, for many years, manifesting a variety of neurologic and psychiatric disorders. It is characterized by gradual loss of memory and working efficiency and associated with high economic and quality-of-life costs. So far there are no definitive premortem diagnostic tools and effective therapeutics available for AD.
The pathogenic mechanisms responsible for the origin and development of the AD are unknown. The research field has mostly been concentrated on the role of amyloid-beta peptides (Abeta) stemming from the apparent fact that these peptides are formed in the brain of AD patients. Аbeta is the major amyloid component of amyloid deposits known as extracellular senile plaques that induce slow neuronal degeneration in the brains of AD patients (1). According to the amyloid cascade hypothesis (2) , which have been most popular in last two decades, extracellular accumulation of Abeta in the central nervous system initiates a reaction cascade leading to widespread neuronal dysfunction, complex pathology and clinical manifestation of disease (3) .
More recent studies on neurons in culture have raised the possibility that neuronal dysfunction and degeneration could be caused by an intraneuronal gradual accumulation of Abeta rather than by an extracellular process (4, 5). This "intracellular hypothesis" is based on transgenic mouse line studies that have demonstrated that Abeta was generated within neurons (6). The supporting evidence includes the demonstration of Abeta occurence within mitochondria of brains from AD patients (4). Using isolated rat brain and muscle mitochondria, Aleardi et al. (2005) observed initial mitochondrial accumulation of Abeta 25−35 and Abeta 1−42 following a short-time incubation with toxic aggregates of Abeta and subsequently, a progressive impairment of both physical and functional properties of the mitochondrial inner membrane (7).
Evidence suggests that Abeta is a key factor in the pathogenesis of AD and it has been proposed that mitochondria are involved in the biochemical pathway by which Abeta can lead to neuronal dysfunction. Numerous investigations performed on animal models of AD, various cell cultures, and isolated mitochondria treated with Abeta revealed defects in mitochondria. In this review, we discuss extensive details about mitochondrial toxicity of Abeta including their adverse effects in mitochondria from human and animal cells, the effects of Abeta on various mitochondrial processes, and molecular mechanisms underlying mitotoxicity of Abeta. This report adds to and expands the recent review by Pagani and Eckert (2011) (8). Although work in this area spans with the beginning of the 21st century, comprehensive understanding of these molecular mechanisms remains a non-trifling task.
Abeta ABUNDANCE AND SPECIES
Abeta is the proteolytic product formed by processing of amyloid precursor protein (1, 10, 11). At least 18 different forms of Abeta were determined in cerebrospinal fluid (CSF) samples from patients who underwent lumbar puncture to exclude infectious disorders of the central nervous system using immunoprecipitation (12). This semiquantitative work has established that numerous cleavage products are created in the brain. Although Abeta is targeted as one of the primary causes of AD, Abeta is constitutively secreted by mammalian cells and normally occurs in plasma and CSF (1, 13). It is also a generic soluble metabolite normally detected throughout the body in blood plasma, brain tissue, urine, tissues, and non-neuronal cells (1, 14, 15 is often selected as a model for fulllength Abeta because it retains both its physical and biological properties, while its short length readily allows derivatives to be synthesized and studied (25). These properties were identified 25 years (26).
Abeta deposition can occur in multiple sites throughout the body in AD. Growing evidence indicates that not only brain but peripheral tissues and cells are affected by AD, including skin, subcutaneous tissue and intestine (27), heart (28), CSF, plasma, urine and blood cells (erythrocytes, platelets, and leukocytes) (6, 29-32).
Numerous defects in a periphery (where, as a rule, amyloid plaques do not accumulate) in AD provide some support for the hypothesis that AD is a systemic disorder.
Abeta EFFECTS IN ISOLATED MITOCHONDRIA
Most studies were performed using Abeta 25−35 , with about 30% of others, Abeta 1-40 , Abeta 1−42 and Abeta 31−35 (Table 1 ). All Abetas studied exerted certainly effects on many mitochondrial processes. The following defects or impairments were widely presented in the literature: decreases in Complex I, II+III and IV activities, State 3 respiration, ADP/O ratio and respiratory control index, mitochondrial ATP synthesis, ATPase activity and mitochondrial membrane potential, calcium capacity of mitochondria and Ca-induced respiration, pyruvate dehydrogenase and alphaketoglutarate dehydrogenase activities and GSH content, uncoupling of oxidative phosphorylation, increase in mitochondrial reactive oxygen species (ROS), hydrogen peroxide (H 2 O 2 ) and © 1996-2015 malondialdehyde production, opening of the mitochondrial permeability transition pore (PTP), and release of mitochondrial cytochrome c. These unambiguously adverse effects were typical in all mitochondrial preparations studied, including rat brain, forebrain, neocortex mitochondria, rat nonsynaptic brain, muscle, liver mitochondria, and mouse brain mitochondria.
The mitochondrial permeability transition and the PTP, identified as the mitochondrial megachannel play a central role in the mitochondrial function and neuronal cell death (52, 53). PTP is the protein complex containing the voltage dependent anion channel in the outer membrane, the adenine nucleotide translocase in the inner membrane, and cyclophilin D in the mitochondrial matrix (54). Cyclophilin D translocation to the inner membrane triggers opening of the PTP (55-57). Opening of PTP leads to swelling of the mitochondrial matrix, dissipation of the inner membrane potential, and generation of ROS. The consequence of opening of the pore is also outer membrane rupture and the release of apoptotic mediators, such as cytochrome c, apoptosis inducing factor (Aif-1), and Smac/ DIABLO, and procaspases from the intermembrane space to cytosol (58) (59) (60) (61) .
The studies discussed above were performed mostly on mitochondria isolated from rat brain and other tissues. They evidenced a deleterious action of Abeta on mitochondrial respiration (7, 36, 41, 44, 45), ATP synthesis (7, 33, 35), and the activity of various enzymes involved in energy production, such as enzyme Complexes I, II+III and IV of the mitochondrial respiratory chain (7, (33) (34) (35) Thus, the mechanisms of mitotoxicity of externally added Abeta include injuries of the respiratory chain, an inhibition of a number enzyme activities, a stimulation of oxidative stress in mitochondrial membranes and matrix (62) . Such the picture is characteristic of mitochondria from any donor tissue studied. Table 2 Thus, the cellular mechanisms of mitotoxicity of externally added Abeta include injuries of mitochondrial respiratory chain and the machinery for its components synthesis, an inhibition of a energy-producing enzyme activities and axonal transport of mitochondria, a stimulation of oxidative stress in mitochondrial membranes and matrix. Such the picture is characteristic of mitochondria occuring in any cell studied, neuronal and non-neuronal by nature.
Abeta EFFECTS ON MITOCHONDRIA WITHIN INTACT CELLS

Abeta EFFECTS ON MITOCHONDRIA IN VIVO
Some effects of Abeta 25−35 , Abeta 1-40 , Abeta 1−42 and Abeta 31−35 administered to animals are shown in Table 3 .
In in vivo experiments, increase in oxidative stress was observed in the rat hippocampal © 1996-2015 Increase in the expression levels of voltage-dependent anion channel gene, adenine nucleotide translocator gene, and cyclophilin D gene in mitochondria isolated from rat hippocampal neurons on 7-21 days after chronic infusion of Abeta 25-35 bilaterally into hippocampal area CA1 were not studied in in vitro experiments (106) . Especially, chronic intracerebroventricular injection of Abeta 25−35 or Abeta 1-40 in rats resulted in much elevation of proteolytic enzyme activity such as caspase 3, caspase 9, calpain-1, calpain-2, cathepsin B, and cathepsin D as well as pro-oxidant monoamine oxidase-B activities in cerebellar, cortical and hippocampal mitochondria, and a suppression of antioxidant catalase and glutathione peroxidase activities in cortical mitochondria (46, 47, 102). Decrease in brain mitochondrial glutathione peroxidase activity was observed after an acute dose of Abeta 25-35 into hippocampus (104). Brain mitochondrial Mn-superoxide dismutase activity decreased after 14 days of chronic dosage of Abeta 1-42 into the lateral cerebral ventricle (103) , although this activity in rat cortical mitochondria increased after 5 days of chronic intracerebroventricular infusion of Abeta 1-40 (46, 47, 102).
The above findings suggest that toxicity mechanisms of Abeta injected into the brain include physical injuries of mitochondria and induction (or redistribution) of a number mitochondrial catabolic enzymes, that can decomposite the key structures determining mitochondrial function. This is characteristic of cerebral cortical, cerebellar, hippocampal and whole brain mitochondria.
ADEQUACY OF THE MODELS USED
The above data indicated that all the experimental models used, isolated mitochondria, in vitro intact cells and in vivo brain tissue, appeared indistinct, in principle by Abeta toxicity to mitochondria. This similarity seems to be of fundamental importance and co-incident to mitochondria of practically any tissue or cell. So, Abetas do impair energy metabolism, but Abetainduced impairement of energy metabolism is not specific to neurons.
The three models were investigated at virtually the same Abeta concentrations. Thereupon, the question arises whether added concentrations and 2 µM Abeta 1-42 in AD patients. The steady state Abeta 1-40 levels in CSF were found to be 5-25 ng/ml (1-6 nM) in healthy volunteers and subjects diagnosed with AD (109) . As for Abeta levels in rodents, huge amounts of the Abeta 1-40 plus Abeta 1-42 sum were found in brain regional mitochondria from two mouse genotypes bearing the amyloid precursor protein mutations: 12-16, 10-17, 2-7 and 0.3-0.4 nmol/mg protein in cerebral, hippocampal, striatal and amygdal mitochondria, respectively (110), i.e. 0.3 to 17 mM concentrations. Even if printer's errors were of three orders of magnitude, then the level of intramitochondrial Abeta (0.3 to 17 µM) appeared to be unusually high. The concentration gradient of two to three orders of magnitude drives the influx of Abeta from neuronal cells to the CSF in both healthy and AD subjects. In order to direct the Abeta concentration gradient from outside to inside, the external Abeta concentration has be higher than the internal one. © 1996-2015 Thus, added concentrations and injected doses of Abeta were adequate in the three models.
Abeta PENETRATION INTO THE MITOCHONDRION
Abetas represent a group of proteins that polymerize into cross beta-sheet amyloid species. When a synthetic Abeta is injected into an animal or added to the incubation medium of cells or mitochondria and affects any mitochondrial process or function, it means that the Abeta enters tissue, cell and mitochondria. Other direct way appears to be absent. To be internalized into a cell and/ or the mitochodrion, exogenous Abeta would pass the hematoencephalic barrier and penetrate across the cellular and/or mitochondrial membranes.
For different reasons, the similarity of Abeta toxicity to mitochondria in the three experimental models is unlikely to be the case. First, it contravenes the doctrine that all the cellular, outer and inner mitochondrial membranes are impermeable for low molecular mass metabolites and cations, incuding the ammonia molecule and proton, let alone for high molecular mass proteins and conjugates. Nonetheless, Abeta proteins do affect mitochondria.
It is unknown how Abeta crosses the blood-brain barrier to act on susceptible cells within the brain and blood vessels. Mechanisms of Abeta transport at the level of the neuronal cell membrane are being studied (111) , but remain to be fully elucidated. However, it is obvious that the plasma membrane of the neuronal or non-neuronal cell is the biggest physical impediment to Abeta influx. Petersen et al. (2008) recently discussed the access of Abeta to mitochondria (112) . The authors hypothesized that Abeta is transported into mitochondria via the translocase of the outer membrane (TOM) machinery. TOM has been proposed by Neupert and Herrmann (2007) as a mechanism of translocation of mitochondrial preproteins from the cytosol into mitochondria (9). This hypothesis, however, has not been formally confirmed and has certain limitations and obscurities. Three surface receptor components of TOM are believed to recognize preproteins, whereas four membrane-embedded subunits form the translocation pore of about 2 nm in diameter (113) . There are no data on recognizing Abeta by these (or other) mitochondrial receptors. Alzheimer's disease neuritic and vascular Abetas present at the average ratio of monomers, dimers, and trimers as 55:30:15 (114) . However, only oligomeric Abetas are toxic to cells and mitochondria. So, for example, when aggregated Abeta 1-42 and Abeta 25-35 were incubated with isolated rat brain and muscle mitochondria, it resulted in reduced respiration rate, ATP synthesis and ATP/O ratio, inhibited complexes I, III and IV activities, induced H 2 O 2 production and cytochrome c release (7). Oligomeric and fibrillar, but not monomeric Abeta 1-42 caused the mitochondrial dysfunction in mouse cortical brain cells (81) . Oligomeric Abeta 1−42 generated the maximal effect on mitochondrial superoxide flash incidence in neural progenitor cells, whereas these cells treated with Abeta 1−42 monomers did not show any change in mitochondrial superoxide flash incidence (72). Aggregated Abeta 1-40 stimulated H 2 O 2 production by rat brain mitochondria in vivo and in vitro while disaggregated Abeta 1-40 did not so (46, 47).
Dimeric and trimeric components of Abeta peptides have molecular masses 9.0 and 13.5 kDa, respectively. Atomic force microscopy and electron microscopy rotary shadowing revealed that the monomers polymerized into 8−10-nm filaments, whereas the dimers generated prolate ellipsoids measuring 3−4 nm in diameter (114) . Schwartz and Matouschek (1999) have determined the effective internal diameter of the protein import channel in the mitochondrial outer membrane to be between 2 nm and 2.6 nm during translocation, much less than that necessary for the dimeric Abeta passage (115) .
Furthermore, PTP is potential dependent and allows molecules with a molecular weight less than 1500 to pass the inner membrane (116) . The PTP, called porin, is a protein complex at contact sites between the inner and outer mitochondrial membranes. At a contact site, the voltage dependent anion channel is built-in outer membrane and continued the adenine nucleotide translocase channel that built-in the inner mitochondrial membrane (54). The open state of mitochondrial porins in pig heart, rat heart, rat liver, and yeast has effective diameters of about 1.7. nm (117) . The diameter of most pores would allow the permeation of substances up to a molecular weight of 2500 (118), that is much less than a molecular weight of thrimeric, dimeric and monomeric Abeta.
Thus, there is no pore of a large enough size in the outer mitochondrial membrane to be capable of Abeta oligomer translocating into the intermembrane space. © 1996-2015
The TIM23 complex, the translocase of the inner mitochondrial membrane, is the major preprotein translocase in the inner membrane of the mitochondrion (9). The pore sizes of the TIM23 channels is proposed to be lower than that of the TOM channels (119) .
Other authors suggested a hypothesis that oligomeric Abeta, in contrast to monomeric Abeta, has the ability to permeabilize cellular membranes and lipid bilayers thereby entering mitochondria (8, 120). They claimed that these mechanisms might explain why exogenous aggregated Abetas affect mitochondrial function, but not disaggregated Abeta. It seems to be the unproven and hardly possible assumption.
Exogenous Abeta penetration into the mitochondrial matrix can be facilitated by trivial rupture of both outer and inner mitochondrial membranes, as a consequence of the inadequate preparative procedures employed. For example, isolated nonsynaptic brain mitochondria having respiratory control ratio of 1.3 (41) cannot be considered as intact mitochondria. Such mitochondrial preparation appears to be similar to leaky and uncovered bucket. In other case, isolated brain mitochondria were stored at 4°C until being used (81) . The respiration parameters of such preparations were as followed: State 3 respiration rate of 90 pmol/s per mg of protein with succinate as a substrate and 140 pmol/s per mg of protein with malate/glutamate as substrates (81) . These figures correspond to 5.4 and 8.4 nmol/min per mg of protein, respectively, and such mitochondrial preparation cannot be considered as functional mitochondria (that usually have the State 3 respiration of 100 nmol/min per mg of protein, by order of magnitude). Mitochondria can be easily done permeable by incubation them for 20 min at 25 o C with or without Abeta (7) or for 10 min at 37°C (46). Do Abetas accumulate in mitochondria in an amount sufficient to elicit their hurtful effects? After 2-24 h treatment of SK-N-AS human neuroblastoma cells with Abeta 1−42 , one to three gold particles per single mitochondrion (including the outer membrane, inner membrane, cristae and matrix) were seen using JNAbeta 1−42 antibody and electron microscopy (50). One to ten gold particles, or 108 gold particles from 20 mitochondria, on an average 5 particles per single mitochondria were counted in human cortical brain biopsy (112) . Such amyloid particles count is unlikely to influence directly on the mitochondrial respiratory chain containing 17000 molecules of each cytochrome pigment and about 130000 molecules of respiratory pigments in each mitochondrion (121). Calpain-1 and calpain-2 activities are located in the mitochondria and lysosomes as well, and they increase many-fold after the chronic injection of rats with Abeta 25-35 : from 3.5 to 24 times on day 7 and from 7 to 42 times on day 14 (100, 101). The mechanism underlying this increase is presently unknown, although synaptic membrane NMDA receptors and mitochondrial Ca 2+ influx appear to be involved. The dynamics of the enzymes suggests that the lysosomal membrane and particularly mitochondrial membranes are gradually and greatly damaged under the influence of Abeta 25-35 , allowing cytosolic calpains to enter the organelles. Another possibility is that calpains are constitutively expressed in the inactive lysosomal form and are activated by Abeta, e.g., as a result of increase in free cytosolic Ca 2+ .
CALCIUM AND Abeta TOXICITY TO MITOCHONDRIA
Chronic administration of Abeta 25-35 induces activation of mitochondrial caspase-3 and caspase-9. Activities of caspases 3 and 9 in mitochondria from three brain regions, neocortex, cerebellum, and hippocampus, increased 2-to 3-fold after 14-day course of Abeta 25-35 infusion (100, 101). About 3-fold increase in mitochondrial caspase 3 and caspase 9 activities was observed in Abeta 1-42 -or Abeta 25-35 -treated human SH-SY5Y neuroblastoma cells (67), human teratocarcinoma cells Ntera2 (63) , primary cortical neuron cultures (88) , primary rat cortical neurons (83) , murine cerebral endothelial cell line (86, 95) , rat brain endothelial cell line RBE4 (71), and rat pheochromocytoma cells PC12 (129) .
Elevation of mitochondrial cathepsin B and D (and of cytosolic alpha-galactosidase and beta-galactosidase) activities in the hippocampus (100, 101) suggests that a lesion of the lysosomal membrane, and efflux of lysosomal glycohydrolases and proteases into the cytoplasm and their intake by mitochondria occur by chronic administration of Abeta [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , and that these changes are involved in neurodegeneration. 
Isolated
CONCLUSION
Abeta peptides exert their harmful effects by impairing energy metabolism in mitochondria isolated from any cell studied to day. The impact of Abeta is seen in a multitude of mitochondrial © 1996-2015 functions, in all isolated mitochondria, cultured cells, and whole organisms. The minimal molecular size of oligomeric Abeta (such as Abeta 1-40 or Abeta 1-42 ) achieves 8-9 kDa or 3-4 nm that does not allow to penetrate the outer and inner mitochondrial membranes. Thus, Abetas can cause mitochondrial dysfunction indirectly, either only in damaged mitochondrial population or by the mechanisms of Abeta signaling.
4.
Fernandez-Vizarra P, AP Fernandez, S Castro-Blanco, J Serrano, ML Bentura, R 
